drugset / Trial / NCT00002505

Tumor Cell Vaccine in Treating Patients With Advanced Cancer

NCT00002505

Treatment

Summary

RATIONALE: Vaccines made from the patient's cancer cells may make the body build an immune response and kill their tumor cells. PURPOSE: Randomized phase II trial to study the effectiveness of autologous tumor cell vaccination plus immunologic adjuvant in treating patients who have metastatic cancer.

Timeline

Start
1992-08
Primary completion
2002-08
Completion
2006-05

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Interferon gamma-1b Protein / enzyme biologic 1e+08 iu Subcutaneous
Subject tumor cell lysate vaccine therapy Vaccine 1e+07 cells Subcutaneous
Background filgrastim Protein / enzyme biologic

Indications

No indication recorded.